Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDI-Based Organic Small Molecule Regulated by Inter/Intramolecular Interactions for Efficient Solar Vapor Generation.

Small (Weinheim an der Bergstrasse, Germany)·2023
Same author

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.

EBioMedicine·2023
Same author

Nomogram of uveal melanoma as prediction model of metastasis risk.

Heliyon·2023
Same author

Dual-Responsive Drug-Delivery System Based on PEG-Functionalized Pillararenes Containing Disulfide and Amido Bonds for Cancer Theranostics.

Chembiochem : a European journal of chemical biology·2023
Same author

Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.

ACS medicinal chemistry letters·2023
Same author

Common and distinct functional brain network abnormalities in adolescent, early-middle adult, and late adult major depressive disorders.

Psychological medicine·2023

Related Experiment Videos

Translating cholesterol guidelines into primary care practice: a multimodal cluster randomized trial.

Charles B Eaton1, Donna R Parker, Jeffrey Borkan

  • 1Department of Family Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Charles_Eaton@mhri.org

Annals of Family Medicine
|November 16, 2011
PubMed
Summary

Patient activation and physician tools did not significantly improve cholesterol goals in a primary care trial. However, higher e-health tool use correlated with better screening and treatment outcomes.

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Health Services Research
  • Digital Health

Background:

  • Adherence to National Cholesterol Education Program guidelines is crucial for managing dyslipidemia.
  • Primary care settings face challenges in optimizing cholesterol screening and treatment.
  • E-health interventions, including patient activation and physician decision support, are being explored to improve chronic disease management.

Purpose of the Study:

  • To evaluate the effectiveness of a combined patient activation and physician decision support tool intervention compared to usual care for improving cholesterol management.
  • To assess adherence to National Cholesterol Education Program guidelines regarding hyperlipidemia screening and achieving lipid goals.

Main Methods:

  • A 1-year cluster randomized controlled trial involving 30 primary care practices and 4,105 patients.
  • Intervention group utilized patient activation kiosks and physician decision support tools.
  • Primary outcome: percentage of patients screened for hyperlipidemia and meeting low-density lipoprotein (LDL) and non-high-density lipoprotein (HDL) cholesterol goals.

Main Results:

  • No statistically significant difference in screening rates or achievement of LDL/non-HDL cholesterol goals between intervention and usual care groups using intent-to-treat analysis.
  • Post hoc analysis: High use of patient activation kiosks was associated with increased patient screening (OR=2.54).
  • Post hoc analysis: High use of physician decision support tools correlated with patients achieving LDL (OR=1.27) and non-HDL (OR=1.23) goals.

Conclusions:

  • The integrated intervention did not demonstrate significant improvements in cholesterol management via intent-to-treat analysis.
  • Frequent utilization of e-health tools (patient activation and decision support) showed a potential benefit in dyslipidemia screening and management.
  • Further research is needed to enhance the adoption and integration of user-friendly, patient-centered e-health tools for chronic disease risk factor management.